US-based medical device solutions provider Argon Medical is set to acquire certain assets of Accurate Medical Therapeutics from French medical imaging company Guerbet.
The assets to be acquired include the SeQure and DraKon microcatheters.
Microcatheters are commonly used in interventional procedures to introduce therapeutic agents or devices into the small vessels delivering blood to a tumour or abnormality.
Upon the close of the acquisition, Argon will transition manufacturing of the SeQure and DraKon catheters to the company’s primary manufacturing facility in Athens, Texas.
Argon intends to re-commercialise both microcatheters in all markets where they were sold previously and evaluate new opportunities to supply these products to new markets.
Argon Medical president and CEO George Leondis said: “Adding the SeQure and DraKon microcatheters to our existing product portfolio marks an important first step in expanding the products we offer interventional oncologists beyond diagnostic procedures and into therapeutic delivery.
“As we do so, we also expand the ways in which we can improve the lives of patients and caregivers through the delivery of best-in-class medical devices and superior service, in alignment with our company mission.”
According to Argon, physicians often select a microcatheter based on the catheter’s ability to navigate to the target and its compatibility with therapeutic agents or devices.
Both SeQure and Drakon microcatheters are easy to navigate and widely compatible.
SeQure is the only reflux control microcatheter designed to create a fluid barrier that directs the flow of therapeutic agents and devices toward the intended target.
The addition of SeQure and Drakon microcatheters will extend its portfolio of oncology offerings to include therapeutic devices and accessories, said the medical device company.
EmboPartners co-founder and interventional radiologist Neal Khurana said: “A microcatheter can make or break a procedure. A well-designed microcatheter determines whether you achieve precise navigation, efficient delivery of embolic materials, and ultimately, optimal patient outcomes.
“The DraKon and SeQure microcatheters have become preferred tools in my practice due to their dependable trackability through tortuous vessels, the performance of their hydrophilic coating, and their ability to deliver contrast and embolics efficiently, even through the smallest catheter sizes.”
